For more than 120 years, Abbott has been in the business of developing and producing pharmaceutical products. Since the 1960s, Abbott has expanded its focus to provide our customers with high-quality, innovative, cost-effective Biologics, High Potency and Finished Goods Contract Manufacturing services and Active Pharmaceutical Ingredients to benefit the companies that put their trust in us.
- Focus : Manufacturer
- Employees: 10,001+
- Industry : Pharma
News about Abbott
08-Jul-2021 | business & finance
Francisco Partners to Acquire STARLIMS
Francisco Partners, a leading global investment firm that specializes in partnering with technology businesses, announced that it has signed a definitive ...
20-Mar-2020 | research and development
Abbott Receives FDA Emergency Use Authorization and Launches Test to Detect Novel Coronavirus
Company scaling up production at its U.S. manufacturing location
14-Sep-2018 | business & finance
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
For the sixth consecutive year, Abbott has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI). Abbott is one of ...
02-Jan-2017 | business & finance
Abbott acquisition of St. Jude Medical set to close
Abbott announced it intends to close the acquisition of St. Jude Medical, Inc. The announcement follows receipt of all regulatory clearances necessary for ...
20-Sep-2016 | business & finance
Abbott to sell Abbott Medical Optics to Johnson & Johnson for $4.325 billion
Abbott announced that it will sell Abbott Medical Optics, its vision care business, to Johnson & Johnson for $4.325 billion in cash. "We've been actively ...
03-Sep-2015 | research and development
Abbott announces results of its naturally dissolving stent
First Trial in Japan Meets Primary Endpoint
08-Jan-2013 | business & finance
Abbott completes separation of research-based pharmaceuticals business
Abbott announced it has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical ...